E
FENC icon

Ergoteles’s Fennec Pharmaceuticals FENC Stock Holding History

Ergoteles’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-91,434
Closed -$861K – 1347
2021
Q3 		$861K Sell
91,434
-906
-1% -$6.8K 0.03% 421
2021
Q2 		$673K Buy
+92,340
New +$616K 0.02% 660

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles's FENC Position: Q4 2021 in Review

Ergoteles sold out of Fennec Pharmaceuticals (FENC) in Q4 2021, closing a stake of 91,434 shares — an estimated $861K sold.

Ergoteles first reported a position in FENC in Q2 2021 and held it in 2 quarters. The position peaked at $861K in Q3 2021. 30 funds tracked by Wall St. Rank hold FENC as of Q4 2021.

  • Ergoteles reported no remaining Fennec Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Ergoteles sold 91,434 Fennec Pharmaceuticals shares in Q4 2021, an estimated $861K.
  • Ergoteles first reported a position in Fennec Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Ergoteles's Fennec Pharmaceuticals position peaked at $861K in Q3 2021.
  • 30 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.